ADVI SAVEs Analysis: COVID-19 Vaccine Uptake
Caitlin Sheetz, MPH
December 19, 2023
ADVI Health’s Strategic Analytics, Values and Economics (SAVEs) team recently studied the COVID-19 vaccination uptake rate in Medicare Fee-For-Service (FFS) patients in the 2023 winter season.
Overall, the data shows that older white patients with chronic conditions are getting vaccinated at higher rates (figure 1).
Figure 1: Medicare FFS Beneficiaries and COVID-19 Vaccination Rates
Conversely, Black and Hispanic patients’ proportions doubled in the non-vaccinated group compared to the vaccinated (figure 2).
Figure 2: Percentage of Medicare FFS Beneficiaries and COViD-19 Vaccination Rate by Patient Proportions
Additionally, the non-vaccinated group accounted for 15 percent of dually eligible Medicare and Medicaid patients and 16 percent of low-income subsidy (LIS) patients. The vaccinated group consisted of only 7 percent for dual eligible and LIS (figure 3).
Figure 3: Percentage of Medicare FFS Beneficiaries and COVID-19 Vaccination Rate for Dual Eligible and LIS
The SAVEs team will continue to follow this issue and changes that may impact your business. If you are interested in additional analysis related to COVID-19 please get in touch.
Caitlin Sheetz, MPH
Senior Vice President and Head of Strategic Analytics, Value and Economics
CEO insights
Related articles
Real analysis from people who’ve been there
RAND/UCLA Modified Delphi Panels
ADVI Health partners with pharmaceutical and biotech organizations to advance their evidence generation and market access strategies. We support complex research questions through primary research (e.g., …
Caitlin Sheetz, MPH
June 23, 2026
The 2026 Rare Disease Reality
Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …
Marc Samuels, JD, MPH
February 26, 2026
How HEOR and Real-World Evidence Are Reshaping Decisions in 2026
By 2026, health economics and outcomes research (HEOR) and real-world evidence (RWE) will look less like a supporting function and …
2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption
In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …
Marc Samuels, JD, MPH
December 16, 2025
Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care
CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …
Alicia Silver, MPP
November 21, 2025
Real-World Effectiveness vs Clinical Trial Efficacy in Medicare
The Inflation Reduction Act (IRA) has ushered in a new era of drug pricing negotiations in the US. For the …
Why is Medicare Data Central to IRA Negotiations?
The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …
ADVI Analysis: MACPAC October 2024 Meeting
MACPAC held a meeting on October 31 and November 1, 2024 (link). The following relevant topics were discussed: ADVI Angle …
Charles Sewell
November 11, 2024
Reach out
Own your edge
We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.